Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced Solid Tumors with Genomic Instability
NCT03428802Phase 2Active, not recruiting
- Sponsor
- Rutgers University
- Start
- Mar 2018
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in solid tumor, sponsored by Rutgers University. Started Mar 2018; status: active, not recruiting.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03428802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428802.